September 25, 2025
In this episode of BioHub Podcast, Pheast CEO Roy Maute joins host Danny Levine to discuss the company’s innovative macrophage focused approach to cancer immunotherapy. Maute explains why CD24 is a promising immune checkpoint target and how Pheast’s lead antibody, PHST001, is engineered to block cancer “don’t eat me” signals while sparing healthy cells. The conversation covers the advantages of activating the innate immune system, the scientific challenges behind developing a best in class CD24 antibody, and Pheast’s strategy for advancing PHST001 toward the clinic.
Listen to the full episode here.